Table 1.
Cx43 expression in clinical samples and its correlation with patients’ clinical outcomes
| Cancer Type | Clinical manifest | Ref. |
|---|---|---|
| Cx43 in primary tumor tissues | ||
| Gastric | Cytoplasmic Cx43; reversely correlated with lymph node metastasis | [19] |
| Pancreatic | Cytoplasmic Cx43; reversely correlated with lymph node metastasis | [36] |
| NSCLC | Cytoplasmic Cx43; reversely correlated with lymph node metastasis | [33, 37] |
| Laryngeal cancer | Cell surface Cx43; reversely correlated with lymph node metastasis, 5-year overall survival, and recurrence | [38, 39] |
| Cx43 in metastatic lesions | ||
| Breast | Cell surface Cx43; increased expression and membrane localization in lymph node metastases | [18] |
| Melanoma | Cx43 mRNA; elevated expression in metastatic tissues | [34] |
| Gastric | Cx43 mRNA; elevated expression in metastatic peritoneal tissues | [29] |
| Breast | Cx43 mRNA; elevated expression in metastatic tissues | [43–45] |
NSCLC Non-small cell lung cancer